Mercado de Tratamento do Comprometimento Cognitivo Leve (MCI) da América do Norte – Tendências do setor e previsão para 2029

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado de Tratamento do Comprometimento Cognitivo Leve (MCI) da América do Norte – Tendências do setor e previsão para 2029

  • Pharmaceutical
  • Publish Reports
  • Feb 2022
  • North America
  • 350 Páginas
  • Número de tabelas: 122
  • Número de figuras: 53

Mercado de tratamento da deficiência cognitiva ligeira (MCI) da América do Norte, por tipo de doença (MCI amnéstico, MCI não amnéstico), tipo de tratamento (medicamentos, terapêutica), via de administração (oral, parentérica, outros), tipo de medicamento (de marca, genéricos) , Tipo de género (masculino, feminino), tipo de idade (criança, adulto, geriátrico), utilizador final (hospitais, clínicas especializadas, cuidados domiciliários, outros), canal de distribuição (farmácias hospitalares, farmácia de retalho), país (EUA, Canadá, México) – Tendências e previsões da indústria para 2029

Análise de mercado e insights : Mercado de tratamento da deficiência cognitiva ligeira (MCI) da América do Norte

Espera-se que o mercado de tratamento do défice cognitivo ligeiro (MCI) ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,0% no período de previsão de 2022 a 2029 e é deverá atingir os 62.355,90 mil dólares até 2029. Espera-se que o amplo portefólio oferecido pelos principais players e a crescente consciencialização sobre o défice cognitivo ligeiro atuem como impulsionadores para o crescimento do mercado.

O défice cognitivo ligeiro (MCI) é uma fase inicial de perda de memória ou outra perda de capacidade cognitiva (como a linguagem ou a perceção visual/espacial) em indivíduos que mantêm a capacidade de realizar a maioria das atividades da vida diária de forma independente. O MCI pode desenvolver-se por múltiplas razões, e os indivíduos que vivem com MCI podem desenvolver demência. O MCI pode ser um estágio inicial do continuum da doença para doenças neurodegenerativas, incluindo a doença de Alzheimer. Em alguns indivíduos, o MCI reverte para a cognição normal ou mantém-se estável.

O défice cognitivo ligeiro (CCL) é caracterizado por um comprometimento num único domínio cognitivo, geralmente a memória (CCL amnéstico), ou um comprometimento moderado em vários domínios cognitivos. A prevalência de DCL entre indivíduos que vivem em ambientes de cuidados continuados varia entre 5% a 10% em muitos lares de idosos até 30%. A forma de MCI mais frequentemente encontrada é o tipo amnésico. Variantes menos comuns de MCI apresentam um comprometimento localizado de outros domínios cognitivos, como a disfunção executiva na degeneração lobar frontotemporal (DLFT).

Os principais fatores que impulsionam o crescimento do mercado global de tratamento do défice cognitivo ligeiro (MCI) são um aumento da população de doentes idosos. Espera-se que a investigação em curso para encontrar a cura perfeita e eficaz impulsione o crescimento do mercado nos próximos tempos. . No entanto, o elevado custo dos procedimentos terapêuticos e os riscos adversos associados ao produto podem dificultar o crescimento do mercado.

O relatório do mercado de tratamento da deficiência cognitiva ligeira (MCI) fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentos de mercado, aprovações de produtos, decisões de estratégia, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado do Tratamento do Comprometimento Cognitivo Leve (MCI), contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto de receita para atingir o seu objetivo desejado.

Âmbito do mercado e tamanho do mercado do tratamento do défice cognitivo ligeiro (MCI)

O mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado com base no tipo de doença, tipo de tratamento, via de administração, tipo de medicamento, tipo de género, tipo de idade, canal de distribuição e utilizadores finais. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • Com base no tipo de doença, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em MCI amnéstico e MCI não amnéstico. Em 2022, prevê-se que o segmento de MCI amnéstico domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido ao aumento da população idosa em todo o mundo.
  • Com base no tipo de tratamento, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em medicamentos e terapia. Em 2022, prevê-se que o segmento dos medicamentos domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido ao seu impacto imediato e eficaz nos sintomas do MCI.
  • Com base na via de administração, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em oral e parentérica, entre outros. Em 2022, prevê-se que o segmento oral domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido ao não invasivo, à elevada adesão dos doentes, ao manuseamento conveniente e à não necessidade de quaisquer condições estéreis específicas.
  • Com base no tipo de medicamento, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em genéricos e de marca. Em 2022, prevê-se que o segmento dos genéricos domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido à relação custo-eficácia em comparação com os medicamentos de marca.
  • Com base no género, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em masculino e feminino. Em 2022, prevê-se que o segmento masculino domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido a um aumento das complicações de saúde mental observadas na população masculina.
  • Com base na idade, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em crianças, adultos e geriátricos. Em 2022, prevê-se que o segmento geriátrico domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido a um aumento da população idosa vulnerável com a maior taxa de aumento na região asiática.
  • Com base nos utilizadores finais, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em hospitais, clínicas especializadas, cuidados domiciliários, entre outros. Em 2022, espera-se que o segmento hospitalar domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido à maior consciencialização sobre um tratamento melhor e mais eficaz durante os internamentos hospitalares.
  • Com base no canal de distribuição, o mercado de tratamento do défice cognitivo ligeiro (MCI) está segmentado em farmácias hospitalares e farmácias de retalho. Em 2022, prevê-se que o segmento da farmácia hospitalar domine o mercado global de tratamento do défice cognitivo ligeiro (MCI) devido ao aumento da interação com prescritores e profissionais de saúde certificados para a utilização de medicamentos antipsicóticos e pagamento garantido.

Análise ao nível do país do mercado de tratamento do défice cognitivo ligeiro (MCI)

O mercado de tratamento do défice cognitivo ligeiro (MCI) é analisado e são fornecidas informações sobre o tamanho do mercado por país, tipo de doença, tipo de tratamento, via de administração, tipo de medicamento, tipo de género, idade, canal de distribuição e utilizadores finais conforme referido acima.

Os países abrangidos no relatório de mercado do tratamento do défice cognitivo ligeiro (MCI) são os EUA, o Canadá e o México.

Espera-se que os EUA dominem o mercado do tratamento do défice cognitivo ligeiro (MCI) devido à investigação em curso para encontrar a cura perfeita e eficaz.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade de marcas globais e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que fornece uma análise de previsão dos dados do país.

O crescimento das atividades estratégicas dos principais players do mercado para aumentar a consciencialização sobre o tratamento do défice cognitivo ligeiro (MCI) está a impulsionar o crescimento do mercado do tratamento do défice cognitivo ligeiro (MCI).

O mercado de tratamento da deficiência cognitiva ligeira (MCI) também fornece análises de mercado detalhadas para o crescimento de cada país num mercado específico. Além disso, fornece informações detalhadas sobre a estratégia dos intervenientes no mercado e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2011 a 2020.

Análise do cenário competitivo e da quota de mercado do tratamento da deficiência cognitiva ligeira (MCI)

O cenário competitivo do mercado de tratamento do défice cognitivo ligeiro (MCI) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado de tratamento do défice cognitivo ligeiro (MCI).

Alguns dos principais players que operam no mercado do tratamento do défice cognitivo ligeiro (MCI) são a Pfizer Inc., a F. Hoffman La Roche Ltd, a Novartis AG, a Accord UK Ltd, a Dr. Co. , UCB SA, Bélgica e WOCKHARDT, entre outros.

Por exemplo,

  • Em julho de 2021, a FDA aprovou o Biogen Aduhelm (aducanumab) para tratar doentes com doença de Alzheimer utilizando o caminho de aprovação acelerada

A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar a pegada da empresa no mercado de tratamento da deficiência cognitiva ligeira (MCI), que também oferece o benefício para o crescimento do lucro da organização.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USERS COVERAGE GRID

2.8 DISEASES TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE

4.2 PORTERS

5 EPIDEMIOLOGY

6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN VULNERABLE GERIATRIC POPULATION

7.1.2 INCREASE IN AIR POLLUTION IMPACTS COGNITIVE PERFORMANCE

7.1.3 INCREASING NATIONAL AND INTERNATIONAL INVESTMENTS IN RESEARCH AND DEVELOPMENT OF COGNITIVE DISORDERS TREATMENT

7.1.4 RISE IN INCIDENCE OF NON-COMMUNICABLE DISEASES DUE TO PHYSICAL INACTIVITY

7.2 RESTRAINTS

7.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

7.2.2 SERIOUS ADVERSE RISK ASSOCIATED WITH MCI TREATMENT DRUGS

7.2.3 HIGH COST OF TREATMENT AND CARE MANAGEMENT IN MCI PATIENTS

7.3 OPPORTUNITIES

7.3.1 PROMOTING PATIENT MENTAL HEALTH PROGRAMS

7.3.2 INNOVATION IN ALTERNATIVE MILD COGNITIVE IMPAIRMENT TREATMENT

7.4 CHALLENGES

7.4.1 LONG PROCESS OF APPROVAL BY REGULATORY BODIES

7.4.2 LACK OF SKILLED PROFESSIONALS

8 COVID-19 IMPACT ON MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY

8.4 STRATEGIC DECISIONS BY MANUFACTURERS

8.5 CONCLUSION

9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 AMNESTIC MCI

9.3 NON-AMNESTIC MCI

10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 MEDICATION

10.2.1 CHOLINESTERASE INHIBITORS

10.2.1.1 DONEPEZIL

10.2.1.2 RIVASTIGMINE

10.2.1.3 OTHERS

10.2.2 BENZODIAZEPINES

10.2.2.1 DIAZEPAM

10.2.2.2 CLONAZEPAM

10.2.2.3 LORAZEPAM

10.2.2.4 TEMAZEPAM

10.2.2.5 ALPRAZOLAM

10.2.2.6 FLUNITRAZEPAM

10.2.2.7 FLURAZEPAM

10.2.2.8 ZOPICLONE

10.2.2.9 OTHERS

10.2.3 GLUTAMATE INHIBITORS

10.2.3.1 RILUZOLE

10.2.3.2 OTHERS

10.2.4 ANTIHISTAMINES

10.2.4.1 CETIRIZINE

10.2.4.2 BROMPHENIRAMINE

10.2.4.3 CHLORPHENIRAMINE

10.2.4.4 CLEMASTINE

10.2.4.5 DIPHENHYDRAMINE

10.2.4.6 FEXOFENADINE

10.2.4.7 LORATADINE

10.2.4.8 OTHERS

10.2.5 MAO INHIBITORS

10.2.5.1 ISOCARBOXAZID

10.2.5.2 PHENELZINE

10.2.5.3 SELEGILINE

10.2.5.4 TRANYLCYPROMINE

10.2.5.5 OTHERS

10.2.6 PROTON PUMP INHIBITORS

10.2.6.1 ESOMEPRAZOLE

10.2.6.2 LANSOPRAZOLE

10.2.6.3 OMEPRAZOLE

10.2.6.4 RABEPRAZOLE

10.2.6.5 PANTOPRAZOLE

10.2.6.6 OTHERS

10.2.7 ALTERNATE THERAPY

10.2.7.1 VITAMIN E

10.2.7.2 GINKO

10.2.7.3 OTHERS

10.2.7.4 OTHERS

10.3 THERAPY

10.3.1 COGNITIVE STIMULATION THERAPY

10.3.2 COGNITIVE BEHAVIORAL THERAPY (CBT)

11 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 SYRUP

11.2.3 OTHERS

11.3 PARENTERAL

11.3.1 INTRAVENOUS

11.3.2 INTRAMUSCULAR

11.3.3 OTHERS

11.4 OTHERS

12 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERICS

12.3 BRANDED

13 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER

13.1 OVERVIEW

13.2 MALE

13.3 FEMALE

14 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE

14.1 OVERVIEW

14.2 GERIATRIC

14.3 ADULT

14.4 CHILD

15 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CLINICS

15.4 HOMECARE

15.5 OTHERS

16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 HOSPITAL PHARMACY

16.3 RETAIL PHARMACY

16.3.1 RETAIL SHOPS

16.3.2 ONLINE PHARMACY

17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 EISAI CO., LTD

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENTS

20.1.5.1 PRODUCT LAUNCH

20.2 TEVA PHARMACEUTICAL INDUSTRIES LTD

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 NOVARTIS AG

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 VIATRIS, INC

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 SUN PHARMACEUTICALS INDUSTRIES LTD

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 PFIZER INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 REVENUE ANALYSIS

20.6.3 PRODUCT PORTFOLIO

20.6.4 RECENT DEVELOPMENT

20.7 ASTRAZENECA

20.7.1 COMPANY SNAPSHOT

20.7.2 REVENUE ANALYSIS

20.7.3 PRODUCT PORTFOLIO

20.7.4 RECENT DEVELOPMENT

20.7.4.1 ACQUISITION

20.8 DR. REDDY’S LABORATORIES LTD.

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENTS

20.9 AUROBINDO PHARMA

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORFOLIO

20.9.4 RECENT DEVELOPMENT

20.9.4.1 PRODUCT APPROVAL

20.1 F.HOFFMANN-LA ROCHE LTD.

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 ABBVIE INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANALYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENT

20.11.4.1 DATA PRESENTATION

20.12 ACCORD-UK LTD

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 CIPLA INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 REVENUE ANALYSIS

20.13.3 PRODUCT PORTFOLIO

20.13.4 RECENT DEVELOPMENT

20.14 HIKMA PHARMACEUTICALS PLC

20.14.1 COMPANY SNAPSHOT

20.14.2 REVENUE ANALYSIS

20.14.3 PRODUCT PORTFOLIO

20.14.4 RECENT DEVELOPMENTS

20.15 JOHNSON & JOHNSON SERVICES, INC.

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 JUBILANT PHARMA LIMITED

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 LANNETT

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENT

20.18 LUPIN

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENT

20.18.4.1 AGREEMENT

20.19 MALLINCKRODT PHARMACEUTICALS

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENT

20.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

20.20.1 COMPANY SNAPSHOT

20.20.2 REVENUE ANALYSIS

20.20.3 PRODUCT PORTFOLIO

20.20.4 RECENT DEVELOPMENT

20.21 UCB S.A., BELGIUM

20.21.1 COMPANY SNAPSHOT

20.21.2 REVENUE ANALYSIS

20.21.3 PRODUCT PORTFOLIO

20.21.4 RECENT DEVELOPMENT

20.22 WOCKHARDT

20.22.1 COMPANY SNAPSHOT

20.22.2 REVENUE ANALYSIS

20.22.3 PRODUCT PORTFOLIO

20.22.4 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Lista de Tabela

TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-

TABLE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 NORTH AMERICA AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 NORTH AMERICA NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 6 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 8 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 9 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 10 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 11 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 12 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 13 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 14 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 15 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 18 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 20 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 22 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 NORTH AMERICA GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 NORTH AMERICA BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 27 NORTH AMERICA MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 NORTH AMERICA FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 30 NORTH AMERICA GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 NORTH AMERICA ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 NORTH AMERICA CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 34 NORTH AMERICA HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 NORTH AMERICA SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 NORTH AMERICA HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 39 NORTH AMERICA HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 41 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 45 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 46 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 47 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 48 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 49 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 50 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 51 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 52 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 53 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 54 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 55 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 56 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 58 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 59 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 60 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 61 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 62 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 63 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 64 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 65 U.S. MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 66 U.S. CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 67 U.S. BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 68 U.S. GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 69 U.S. MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 70 U.S. PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 71 U.S. ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 72 U.S. ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 73 U.S. THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 75 U.S. ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 76 U.S. PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 77 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 78 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 79 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 80 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 81 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 82 U.S. RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 83 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 84 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 CANADA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 CANADA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 87 CANADA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 88 CANADA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 89 CANADA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 90 CANADA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 91 CANADA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 92 CANADA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 93 CANADA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 94 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 95 CANADA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 96 CANADA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 97 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 99 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 100 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102 CANADA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 104 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 105 MEXICO MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 106 MEXICO CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 MEXICO BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 MEXICO GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 MEXICO MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 MEXICO PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 MEXICO ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 MEXICO ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 MEXICO THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 115 MEXICO ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 116 MEXICO PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 117 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 118 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 119 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 120 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 121 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 122 MEXICO RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

Lista de Figura

FIGURE 1 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID

FIGURE 8 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019

FIGURE 16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021

FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 21 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)

FIGURE 22 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 24 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 25 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

FIGURE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 27 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021

FIGURE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)

FIGURE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021

FIGURE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)

FIGURE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)

FIGURE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021

FIGURE 37 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)

FIGURE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)

FIGURE 39 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 40 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021

FIGURE 41 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)

FIGURE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 45 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

FIGURE 46 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 47 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 49 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 50 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 52 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 53 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The North America Mild Cognitive Impairment (MCI) Treatment Market size will be worth USD 62,355.90 thousand during the forecast period.
The North America Mild Cognitive Impairment (MCI) Treatment Market growth rate is 9.0% during the forecast period.
The Wide portfolio offered by major players and growing awareness of mild cognitive impairment are the growth drivers of the North America Mild Cognitive Impairment (MCI) Treatment Market.
The disease type, treatment type, route of administration, drug type, gender type, age type, distribution channel, and end users are the factors on which the North America Mild Cognitive Impairment (MCI) Treatment Market research is based.
The major companies in the North America Mild Cognitive Impairment (MCI) Treatment Market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT.